Market Overview

ChemoCentryx Issues Top-Line Interim Results for CCX140, Says Data Showed Statistically Significant Reduction in Protein

Share:
Related CCXI
Benzinga's Top Upgrades, Downgrades For February 11, 2019
85 Biggest Movers From Friday

ChemoCentryx, Inc. (Nasdaq: CCXI) today announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2, and the drug candidate is wholly owned by the Company. Examining data through the first 12 weeks of dosing in the ongoing 52 week trial, in which CCX140 is added on top of the standard of care for diabetic nephropathy patients (i.e., stable doses of angiotensin pathway inhibitors), the drug candidate appears well-tolerated in the patient population to date. The safety observations were consistent with a concurrent analysis by the Company's independent safety data monitoring committee, which independently assessed the interim data and recommended no changes to the ongoing study protocol. In addition, data also showed that patients treated with 5 mg CCX140 once daily experienced a statistically significant reduction of protein in the urine, or proteinuria, as measured by Urinary Albumin Creatinine Ratio (UACR) versus those patients receiving only the standard of care (placebo group), following two weeks of treatment (total study number, n, analyzed at that time point = 332; p<0.05), with continuing downward trends in UACR observed following 8-weeks (n=259) and 12-weeks (n=208) of treatment with CCX140. In pre-specified analyses of subsets of patients in the study, greater reductions in proteinuria were observed, including decreases of approximately 30% in UACR in the CCX140 groups versus those patients only on background medications. The Company indicated that the data support the continued progress of full 52 weeks of dosing in the Phase II trial as planned. Data from the full study are expected in the second half of 2014, which will continue to monitor proteinuria as well as assess additional markers related to kidney function, including serum creatinine and estimated glomerular filtration rate, measures which historically take longer to be detected in clinical trials.

Posted-In: News

 

Related Articles (CCXI)

View Comments and Join the Discussion!

DuPont Fabros Tech Initiates Search Process for Pres; Announces $600M Offering of Senior Notes, $550 Aggregate Principal

NuPathe Reports Allowance of Added US Patent for ZECUITY